About
Portfolio
News
Contact
Contact us
Join Us
Contact
OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads
Job description
Job responsibilities
Education/Experience
Returns
Previous
2022.01.20
Qpex Biopharma Announces Progress on Three Clinical Stage Programs for Antibiotic-Resistant Pathogens and Corporate Update
Next
2021.10.27
Onchilles Pharma Appoints Christopher Twitty, Ph.D., Chief Scientific Officer